108 related articles for article (PubMed ID: 26049107)
41. Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line.
Ren P; Tiede C; Fanning SW; Adams T; Speirs V; Nelson ER; Cheng C; Moore TW; Greene GL; Tomlinson D; Selvin PR
Biophys J; 2022 Oct; 121(19):3651-3662. PubMed ID: 35778844
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
43. Molecular basis and dual ligand regulation of tetrameric estrogen receptor α/14-3-3ζ protein complex.
Somsen BA; Sijbesma E; Leysen S; Honzejkova K; Visser EJ; Cossar PJ; Obšil T; Brunsveld L; Ottmann C
J Biol Chem; 2023 Jul; 299(7):104855. PubMed ID: 37224961
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the
Chitrala KN; Nagarkatti M; Nagarkatti P; Yeguvapalli S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216622
[TBL] [Abstract][Full Text] [Related]
45. Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
Jia S; Miedel MT; Ngo M; Hessenius R; Chen N; Wang P; Bahreini A; Li Z; Ding Z; Shun TY; Zuckerman DM; Taylor DL; Puhalla SL; Lee AV; Oesterreich S; Stern AM
Oncology; 2018; 94(3):176-189. PubMed ID: 29306943
[TBL] [Abstract][Full Text] [Related]
46. Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling.
Dong P; Jiang L; Liu J; Wu Z; Guo S; Zhang Z; Zhou F; Liu Z
PLoS One; 2013; 8(12):e83519. PubMed ID: 24376711
[TBL] [Abstract][Full Text] [Related]
47. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.
Pavlin M; Spinello A; Pennati M; Zaffaroni N; Gobbi S; Bisi A; Colombo G; Magistrato A
Sci Rep; 2018 Jan; 8(1):649. PubMed ID: 29330437
[TBL] [Abstract][Full Text] [Related]
48. A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells.
Yoshimaru T; Ono M; Bando Y; Chen YA; Mizuguchi K; Shima H; Komatsu M; Imoto I; Izumi K; Honda J; Miyoshi Y; Sasa M; Katagiri T
Nat Commun; 2017 May; 8():15427. PubMed ID: 28555617
[TBL] [Abstract][Full Text] [Related]
49. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
Huggins RJ; Greene GL
NPJ Breast Cancer; 2023 Nov; 9(1):96. PubMed ID: 38036546
[TBL] [Abstract][Full Text] [Related]
50. Investigation of binding mechanism and downregulation of elacestrant for wild and L536S mutant estrogen receptor-α through molecular dynamics simulation and binding free energy analysis.
Chinnasamy K; Saravanan M; Poomani K
J Comput Chem; 2020 Jan; 41(2):97-109. PubMed ID: 31602686
[TBL] [Abstract][Full Text] [Related]
51. Circulating oestrogen receptor mutations and splice variants in advanced prostate cancer.
Qu LG; Wardan H; Davis ID; Iddawela M; Sluka P; Pezaro CJ
BJU Int; 2019 Nov; 124 Suppl 1():50-56. PubMed ID: 31090242
[TBL] [Abstract][Full Text] [Related]
52. Structural Basis of Inhibition of ERα-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides.
Xie M; Zhao H; Liu Q; Zhu Y; Yin F; Liang Y; Jiang Y; Wang D; Hu K; Qin X; Wang Z; Wu Y; Xu N; Ye X; Wang T; Li Z
J Med Chem; 2017 Nov; 60(21):8731-8740. PubMed ID: 29045135
[TBL] [Abstract][Full Text] [Related]
53. pH and the Breast Cancer Recurrent Mutation D538G Affect the Process of Activation of Estrogen Receptor α.
de Oliveira VM; Dias MMG; Avelino TM; Videira NB; da Silva FB; Doratioto TR; Whitford PC; Leite VBP; Figueira ACM
Biochemistry; 2022 Mar; 61(6):455-463. PubMed ID: 35238537
[TBL] [Abstract][Full Text] [Related]
54. Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.
Yang J; Li B; He QY
Cell Death Dis; 2018 May; 9(6):580. PubMed ID: 29784973
[TBL] [Abstract][Full Text] [Related]
55. Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery.
McDonnell DP; Norris JD; Chang CY
Cancer Cell; 2018 Feb; 33(2):153-155. PubMed ID: 29438688
[TBL] [Abstract][Full Text] [Related]
56. PGRMC1 Promotes Progestin-Dependent Proliferation of Breast Cancer Cells by Binding Prohibitins Resulting in Activation of ERα Signaling.
Bai Y; Ludescher M; Poschmann G; Stühler K; Wyrich M; Oles J; Franken A; Rivandi M; Abramova A; Reinhardt F; Ruckhäberle E; Niederacher D; Fehm T; Cahill MA; Stamm N; Neubauer H
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830790
[TBL] [Abstract][Full Text] [Related]
57. RSU-1 interaction with prohibitin-2 links cell-extracellular matrix detachment to downregulation of ERK signaling.
Wang M; Liu J; Tu Y; Zhao Z; Qu J; Chen K; Chen Y; Sun Y; Zhao H; Deng Y; Wu C
J Biol Chem; 2021; 296():100109. PubMed ID: 33853759
[TBL] [Abstract][Full Text] [Related]
58. Emerging significance of estrogen cancer coregulator signaling in breast cancer.
Mann M; Krishnan S; Vadlamudi RK
Minerva Ginecol; 2012 Feb; 64(1):75-88. PubMed ID: 22334233
[TBL] [Abstract][Full Text] [Related]
59. Dynamics Insights Into the Gain of Flexibility by Helix-12 in ESR1 as a Mechanism of Resistance to Drugs in Breast Cancer Cell Lines.
Khan A; Ashfaq-Ur-Rehman ; Junaid M; Li CD; Saleem S; Humayun F; Shamas S; Ali SS; Babar Z; Wei DQ
Front Mol Biosci; 2019; 6():159. PubMed ID: 32039233
[TBL] [Abstract][Full Text] [Related]
60. Point-activated ESR1
Simond AM; Ling C; Moore MJ; Condotta SA; Richer MJ; Muller WJ
Genes Dev; 2020 Oct; 34(19-20):1304-1309. PubMed ID: 32912899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
